Absci (NASDAQ:ABSI – Get Free Report) is anticipated to release its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect the company to announce earnings of ($0.1889) per share and revenue of $0.63 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:00 AM ET.
Absci (NASDAQ:ABSI – Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). Absci had a negative net margin of 7,756.38% and a negative return on equity of 61.71%. The firm had revenue of $0.32 million for the quarter, compared to analyst estimates of $0.92 million. On average, analysts expect Absci to post ($0.76) EPS for the current fiscal year and ($0.72) EPS for the next fiscal year.
Absci Stock Performance
Shares of NASDAQ:ABSI opened at $9.97 on Wednesday. Absci has a 52 week low of $2.24 and a 52 week high of $12.54. The company has a market capitalization of $1.71 billion, a PE ratio of -12.46 and a beta of 2.22. The company has a 50 day moving average price of $9.63 and a two-hundred day moving average price of $6.71.
Analysts Set New Price Targets
Several equities analysts have recently issued reports on the stock. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price target on shares of Absci in a report on Wednesday, September 23rd. JPMorgan Chase & Co. upped their price objective on shares of Absci from $14.00 to $15.00 and gave the company an “overweight” rating in a research report on Monday, October 12th. HC Wainwright reaffirmed a “buy” rating on shares of Absci in a research note on Tuesday, October 20th. Wall Street Zen raised Absci from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, KeyCorp lifted their target price on Absci from $16.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, October 16th. Eleven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.50.
Read Our Latest Analysis on Absci
Absci Company Profile
Absci Corporation is a biotechnology company that uses artificial intelligence and laboratory research to discover and develop biologic drugs. Its platform combines generative AI with experimental testing to design and evaluate potential drug candidates, including antibodies and other protein-based medicines. The company also works with pharmaceutical and biotechnology partners on drug discovery programs and advances its own pipeline of potential therapies. Its approach is intended to connect computational design with laboratory validation, helping assess whether designed molecules have useful properties.
Read More
- Five stocks we like better than Absci
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Absci Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Absci and related companies with MarketBeat.com's FREE daily email newsletter.
